This activity was originally presented at the 2026 Breast
Cancer Day of Education.
In collaboration with HOPA & COA.
Program Description
Many patients with metastatic hormone receptor–positive (HR+)/HER2– breast cancer receive multiple lines of therapy over several years. The growing availability of CDK4/6 inhibitors, pathway-targeted agents, and antibody-drug conjugates (ADCs) has improved survival outcomes but also introduced considerable complexity in choosing, sequencing, and transitioning therapies after progression. This session expands on sequencing treatment after progression on CDK4/6 inhibitor–based regimens. Participants will follow case-based scenarios that reflect real-world challenges in interpreting HR+/HER2 progression, preserving endocrine options when appropriate, and avoiding reflexive transitions to chemotherapy when endocrine sensitivity persists, with opportunities for interactive responses and discussion with speakers. Discussion will highlight how to apply sequencing logic when multiple actionable alterations are present and how to recognize when transitioning away from endocrine strategies toward ADCs and other non-endocrine options becomes appropriate, including reframing treatment goals in that setting. Speakers will highlight best practices for oncology pharmacists to optimize treatment continuity, minimize avoidable toxicity, and support patients through the complex, multi-line course of treatment in metastatic HR+/HER2– breast cancer.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 30, 2026
Expiration date: July 30, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.25 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine a foundational sequencing framework for hormone receptor–positive/HER2− (HR+/HER2−) metastatic breast cancer following progression on CDK4/6 inhibitor–based therapy
- Explain common areas of therapeutic uncertainty in HR+/HER2− metastatic breast cancer and how emerging clinical data influence treatment discussions after progression on CDK4/6 inhibitor–based therapy
- Apply patient-centered counseling approaches to support shared decision-making during treatment transitions in HR+/HER2− metastatic breast cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
